Primary adult liver transplantation under tacrolimus

More than 90 months actual follow-up survival and adverse events

A. B. Jain, R. Kashyap, Jorge Rakela, T. E. Starzl, J. J. Fung

Research output: Contribution to journalArticle

37 Citations (Scopus)

Abstract

The introduction of tacrolimus has shown decreased rates of acute and steroid-resistant rejection after liver transplantation (LTx). The aim of the present study is to examine the long-term efficacy and safety of tacrolimus in primary liver transplant recipients. The first 121 consecutive adults (aged > 16 years) who underwent primary LTx at a single center from August 1989 to February 1990 were followed up until August 1997. The mean follow-up was 93.2 ± 1.2 months (range, 90.5 to 96.5 months). Patient survival, graft survival, rate of rejection, and adverse events were examined. The actual 7- year patient survival rate was 67.8%, and the graft survival rate was 63.6%. Infections, recurrence of disease, de novo malignancies, and cardiovascular events constituted the main causes of graft loss and death in the long term. Graft loss related to acute or chronic rejection was rare. The rate of acute rejection beyond 2 years was approximately 3% per year, and most rejections were steroid responsive. Approximately 70% of the patients received only tacrolimus after 1 year. Four patients developed endstage renal disease, and 2 patients underwent kidney transplantation. Hyperkalemia and hypertension were observed in one third of the patients New-onset insulin-dependent diabetes mellitus was observed in 9% and 13% of the patients at the 1-year and 7-year follow-up, respectively. Seven patients developed de novo malignancies, including two skin malignancies. Six patients developed posttransplantation lymphoproliferative disorder during the entire follow-up period. Actual patient and graft survival at 7 years was excellent, and few adverse events developed after the first year. Graft loss from acute or chronic rejection was rare under tacrolimus, and approximately 70% of the patients were steroid free on tacrolimus monotherapy after the first year after LTx.

Original languageEnglish (US)
Pages (from-to)144-150
Number of pages7
JournalLiver Transplantation and Surgery
Volume5
Issue number2
StatePublished - 1999
Externally publishedYes

Fingerprint

Tacrolimus
Liver Transplantation
Survival
Graft Survival
Survival Rate
Steroids
Transplants
Neoplasms
Hyperkalemia
Lymphoproliferative Disorders
Type 1 Diabetes Mellitus
Kidney Transplantation
Hypertension
Kidney
Safety
Recurrence
Skin

ASJC Scopus subject areas

  • Hepatology
  • Surgery

Cite this

Primary adult liver transplantation under tacrolimus : More than 90 months actual follow-up survival and adverse events. / Jain, A. B.; Kashyap, R.; Rakela, Jorge; Starzl, T. E.; Fung, J. J.

In: Liver Transplantation and Surgery, Vol. 5, No. 2, 1999, p. 144-150.

Research output: Contribution to journalArticle

@article{4914d66ee2cb4a1aba588e41272767ef,
title = "Primary adult liver transplantation under tacrolimus: More than 90 months actual follow-up survival and adverse events",
abstract = "The introduction of tacrolimus has shown decreased rates of acute and steroid-resistant rejection after liver transplantation (LTx). The aim of the present study is to examine the long-term efficacy and safety of tacrolimus in primary liver transplant recipients. The first 121 consecutive adults (aged > 16 years) who underwent primary LTx at a single center from August 1989 to February 1990 were followed up until August 1997. The mean follow-up was 93.2 ± 1.2 months (range, 90.5 to 96.5 months). Patient survival, graft survival, rate of rejection, and adverse events were examined. The actual 7- year patient survival rate was 67.8{\%}, and the graft survival rate was 63.6{\%}. Infections, recurrence of disease, de novo malignancies, and cardiovascular events constituted the main causes of graft loss and death in the long term. Graft loss related to acute or chronic rejection was rare. The rate of acute rejection beyond 2 years was approximately 3{\%} per year, and most rejections were steroid responsive. Approximately 70{\%} of the patients received only tacrolimus after 1 year. Four patients developed endstage renal disease, and 2 patients underwent kidney transplantation. Hyperkalemia and hypertension were observed in one third of the patients New-onset insulin-dependent diabetes mellitus was observed in 9{\%} and 13{\%} of the patients at the 1-year and 7-year follow-up, respectively. Seven patients developed de novo malignancies, including two skin malignancies. Six patients developed posttransplantation lymphoproliferative disorder during the entire follow-up period. Actual patient and graft survival at 7 years was excellent, and few adverse events developed after the first year. Graft loss from acute or chronic rejection was rare under tacrolimus, and approximately 70{\%} of the patients were steroid free on tacrolimus monotherapy after the first year after LTx.",
author = "Jain, {A. B.} and R. Kashyap and Jorge Rakela and Starzl, {T. E.} and Fung, {J. J.}",
year = "1999",
language = "English (US)",
volume = "5",
pages = "144--150",
journal = "Liver Transplantation",
issn = "1527-6465",
publisher = "John Wiley and Sons Ltd",
number = "2",

}

TY - JOUR

T1 - Primary adult liver transplantation under tacrolimus

T2 - More than 90 months actual follow-up survival and adverse events

AU - Jain, A. B.

AU - Kashyap, R.

AU - Rakela, Jorge

AU - Starzl, T. E.

AU - Fung, J. J.

PY - 1999

Y1 - 1999

N2 - The introduction of tacrolimus has shown decreased rates of acute and steroid-resistant rejection after liver transplantation (LTx). The aim of the present study is to examine the long-term efficacy and safety of tacrolimus in primary liver transplant recipients. The first 121 consecutive adults (aged > 16 years) who underwent primary LTx at a single center from August 1989 to February 1990 were followed up until August 1997. The mean follow-up was 93.2 ± 1.2 months (range, 90.5 to 96.5 months). Patient survival, graft survival, rate of rejection, and adverse events were examined. The actual 7- year patient survival rate was 67.8%, and the graft survival rate was 63.6%. Infections, recurrence of disease, de novo malignancies, and cardiovascular events constituted the main causes of graft loss and death in the long term. Graft loss related to acute or chronic rejection was rare. The rate of acute rejection beyond 2 years was approximately 3% per year, and most rejections were steroid responsive. Approximately 70% of the patients received only tacrolimus after 1 year. Four patients developed endstage renal disease, and 2 patients underwent kidney transplantation. Hyperkalemia and hypertension were observed in one third of the patients New-onset insulin-dependent diabetes mellitus was observed in 9% and 13% of the patients at the 1-year and 7-year follow-up, respectively. Seven patients developed de novo malignancies, including two skin malignancies. Six patients developed posttransplantation lymphoproliferative disorder during the entire follow-up period. Actual patient and graft survival at 7 years was excellent, and few adverse events developed after the first year. Graft loss from acute or chronic rejection was rare under tacrolimus, and approximately 70% of the patients were steroid free on tacrolimus monotherapy after the first year after LTx.

AB - The introduction of tacrolimus has shown decreased rates of acute and steroid-resistant rejection after liver transplantation (LTx). The aim of the present study is to examine the long-term efficacy and safety of tacrolimus in primary liver transplant recipients. The first 121 consecutive adults (aged > 16 years) who underwent primary LTx at a single center from August 1989 to February 1990 were followed up until August 1997. The mean follow-up was 93.2 ± 1.2 months (range, 90.5 to 96.5 months). Patient survival, graft survival, rate of rejection, and adverse events were examined. The actual 7- year patient survival rate was 67.8%, and the graft survival rate was 63.6%. Infections, recurrence of disease, de novo malignancies, and cardiovascular events constituted the main causes of graft loss and death in the long term. Graft loss related to acute or chronic rejection was rare. The rate of acute rejection beyond 2 years was approximately 3% per year, and most rejections were steroid responsive. Approximately 70% of the patients received only tacrolimus after 1 year. Four patients developed endstage renal disease, and 2 patients underwent kidney transplantation. Hyperkalemia and hypertension were observed in one third of the patients New-onset insulin-dependent diabetes mellitus was observed in 9% and 13% of the patients at the 1-year and 7-year follow-up, respectively. Seven patients developed de novo malignancies, including two skin malignancies. Six patients developed posttransplantation lymphoproliferative disorder during the entire follow-up period. Actual patient and graft survival at 7 years was excellent, and few adverse events developed after the first year. Graft loss from acute or chronic rejection was rare under tacrolimus, and approximately 70% of the patients were steroid free on tacrolimus monotherapy after the first year after LTx.

UR - http://www.scopus.com/inward/record.url?scp=0032981217&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032981217&partnerID=8YFLogxK

M3 - Article

VL - 5

SP - 144

EP - 150

JO - Liver Transplantation

JF - Liver Transplantation

SN - 1527-6465

IS - 2

ER -